Early Itch Response with Abrocitinib is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE 3 COMPARE Trial
Version 2 2022-12-04, 22:31
Version 1 2022-11-22, 18:12
media
posted on 2022-12-04, 22:31 authored by Adis Journals on behalf of:, Sonja Ständer, Shawn G. Kwatra, Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen, Gil Yosipovitch, Fan Zhang, Michael C. Cameron, Ricardo Rojo Cella, Hernan Valdez, Marco DiBonaventura, Claire Feeney<p><strong>Article full text</strong></p>
<p>The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2022</p>
History
Related Materials
- 1.
- 2.
